Across TCGA pan-cancer cohorts, PP2D1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PP2D1 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PP2D1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PP2D1 expression acts as an unfavorable survival marker.
BRCA are the cancer types where PP2D1 Mutation most reproducibly stratifies survival.